Eli Lilly Acquires Psychedelics Firm AtaiBeckley for $2.8B
Eli Lilly is buying AtaiBeckley for $2.8 billion, gaining access to experimental DMT- and MDMA-based treatments as psychedelic therapies attract growing interest.
Eli Lilly announced Monday it will acquire psychedelics developer AtaiBeckley in a deal valued at $2.8 billion, marking one of the largest pharmaceutical bets yet on experimental mental-health treatments derived from psychedelic compounds. The move signals a significant shift in how major drugmakers view once-fringe therapies rooted in substances long classified as controlled drugs.
The acquisition hands Lilly a pipeline of experimental drugs built around DMT — the active compound in ayahuasca — and MDMA, the substance widely known as ecstasy. Both compounds have drawn intense scientific attention in recent years for their potential to treat conditions such as depression, PTSD, and addiction, areas where conventional medications have repeatedly fallen short for millions of patients.
Read more Cribl Acquires CardinalOps to Boost AI Security Operations →
For Lilly, already a dominant force in the pharmaceutical industry through its blockbuster diabetes and obesity drugs, the AtaiBeckley deal represents a calculated expansion into neuropsychiatry at a moment when regulatory attitudes toward psychedelic-assisted therapy are visibly softening. The FDA has previously granted "breakthrough therapy" designations to certain psychedelic compounds, fast-tracking their path through the clinical evaluation process.
The transaction underscores how quickly capital is flowing into the psychedelics space as venture-backed startups and research nonprofits accumulate clinical data that legacy pharma companies cannot easily replicate in-house. Lilly's willingness to write a multibillion-dollar check suggests institutional confidence that at least some of these compounds will eventually clear regulatory hurdles and reach mainstream medicine.
Continue reading at US Top News and Analysis.
